INVESTIGADORES
CHIARELLA Paula
artículos
Título:
Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors
Autor/es:
PAULA CHIARELLA; MARISA VULCANO; JUAN BRUZZO; VERMEULEN MONICA; VANZULLI, SILVIA; ANDREA MAGLIOCO; GABRIELA CAMERANO; VICTOR PALACIOS; GABRIELA C. FERNANDEZ; ROMINA BRANDO FERNANDEZ; MARTÍN A. ISTURIZ; GRACIELA DRAN; OSCAR D. BUSTUOABAD; RUGGIERO RAUL
Revista:
CANCER IMMUNOLOGY IMMUNOTHERAPY
Editorial:
SPRINGER
Referencias:
Año: 2008 vol. 58 p. 701 - 718
ISSN:
0340-7004
Resumen:
Although animals can be immunized against the growth of some tumor implants, most of the attempts to use immunotherapy to cause the regression of animal and human tumors once they become established have been disappointing even in the case that strongly immunogenic tumors were used as target. In this paper we demonstrate that the failure to achieve an efficient immunological treatment against an established strongly immunogenic murine fibrosarcoma, was paralleled with the emergence of a state of immunological unresponsiveness (immunological eclipse) against tumor antigens observed when the tumor surpassed the critical size of 500 mm3. In turn, the onset of the immunological eclipse was coincidental with the onset of a systemic inflammatory condition characterized by a high number of circulating and splenic polymorphonucleated neutrophils (PMN) displaying activation and Gr1+Mac1+ phenotype and an increasingly serum concentration of the pro-inflammatory cytokines TNF-alfa, IL-1beta and IL-6 cytokines and C Reactive Protein (CRP) and Serum A Amyloid (SAA) phase acute proteins. Treatment of tumor-bearing mice with a single low dose (0.75 mg/kg) of the synthetic corticoid dexamethasone (DX) significantly reduced all the systemic inflammatory parameters and simultaneously reversed the immunological eclipse as evidenced by the restoration of specific T-cell dependent concomitant immunity, ability of spleen cells to transfer anti-tumor activity and recovery of immune response-associated transducing signals by spleen T cells. Two other anti-inflammatory treatments by using indomethacin or dimeric TNF-alfa receptor, also partially reversed the immunological eclipse although the effect was not as striking as that observed with DX. The reversion of the immunological eclipse was not enough on its own to inhibit the primary growing tumor. However, when we used the two-step strategy of inoculating DX to reverse the eclipse and then dendritic cells loaded with tumor antigens (DC) as an immunization booster, a significant inhibition of the growth of both, established tumors and remnant tumor cells after excision of large established tumors, was observed, despite the fact that the vaccination alone (DC) had no effect or even enhanced tumor growth in certain circumstances. The two-step strategy of tumor immunotherapy that we present herein is based on the rationale that it is necessary to eliminate or ameliorate the immunological eclipse as a precondition to allow an otherwise ineffective anti-tumor immunological therapy to have a chance to be successful.